Glaukos Announces First Quarter 2024 Financial Results
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include:Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year.Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year.Corneal Health net sales of $18.4 million in Q1 2024 increased 4% year-over-year.Gross margin of approximately 76% and non-GAAP gross margin of approximately 83% in Q1 2024.Raised 2024 net sales guidance to $357 to $365 million, compared to $350 million to $360 million previously.“Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of no
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock [Yahoo! Finance]Yahoo! Finance
- Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockBusiness Wire
- Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally? [Yahoo! Finance]Yahoo! Finance
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Stifel Nicolaus from $110.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos Co. (NYSE: GKOS) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $120.00. They now have an "overweight" rating on the stock.MarketBeat
GKOS
Earnings
- 5/1/24 - Miss
GKOS
Sec Filings
- 6/14/24 - Form 8-K
- 6/5/24 - Form 4
- 6/5/24 - Form 8-K
- GKOS's page on the SEC website